ADDITIONAL INFORMATION 21 21.1 hereabove corresponds to the number of shares purchased, SHARE CAPITAL following the deduction of the number of shares, which have been re-sold; 21.1.1 AMOUNT OF ISSUED CAPITAL • to keep the purchased shares and to subsequently put them up for exchange or as payment in the context of any external As of the date of this Registration Document, our share capital growth transactions; is equal to €605,855.58, divided into 24,234,223 shares, with nominal value of €0.025 per share, fully authorized, subscribed • to ensure the coverage of share purchase option schemes and paid-up. and/or share schemes allocated on a free of charge basis (or similar schemes) in favour of the salaried employees and/ or the corporate officers of the group as wel l as any share 21.1.2 SECURITIES NOT REPRESENTING SHARE allocations pursuant to a company or group savings scheme (or CAPITAL similar scheme) in respect of a company profit sharing scheme As of the date of this Registration Document, we have not issued and/or any other forms of allocation of shares to the salaried any securities not representing the share capital. employees and/or to the corporate officers of the group; • to ensure the coverage of securities giving right to the allocation 21.1.3 SHARES CONTROLLED BY THE COMPANY, of shares of the company in the context of the regulations in TREASURY SHARES AND PURCHASE BY THE force; COMPANY OF ITS OWN SHARES • to carry out the possible cancellation of the acquired shares, in Our Combined General Shareholders’ Meeting of April 12, accordance with the authorization granted or to be granted by 2018 authorized our Board of Directors to implement a the Extraordinary General Meeting. buyback program of our shares, according to the provisions of The maximum purchase price is €24 per share. In case of a Article L.225-209 of the French Commercial Code. transaction affecting the share capital, and notably of a share The maximum number of shares that can be purchased is 5% of consolidation or split, or al location of bonus shares to the the share capital of the Company (at any time whatsoever, such shareholders, the above-mentioned price will be adjusted to the percentage applying to a capital, which shall be adjusted based on same proportion (a coefficient of the ratio between the number the transactions subsequently affecting it). of shares comprising the share capital before the transaction and the number of shares after the transaction). Objectives of the buybacks: The maximum amount of the funds intended for the program of • to ensure the buoyancy of the secondary market or the the repurchase of the shares shall amount to €28,795,704. liquidity of the Company shares through the intermediary of an investment service provider by way of a liquidity agreement During the fiscal year ended December 31, 2017, this buyback in compliance with the code of ethics of the AMAFI (French program was used exclusively within the scope of a liquidity Financial Markets’ Association) admitted by the regulations, it agreement with the objective of stimulating trading or liquidity of being specified that in this context, the number of shares taken the Company’s shares, stipulated with Oddo & Cie as investment into account for the calculation of the limitation referred to services provider. Number of shares purchased 233,068 Average purchase price 5.62 Number of shares sold 215,182 Average selling price 5.69 Total amount of negotiation costs €25,000 Number of shares used in 2017 — Number of shares owned as of December 31, 2017 36,625 Value at average purchase price 205,833 Nominal value 915.625 216– GENSIGHT BIOLOGICS – 2017 Registration Document